AMETEK (NYSE:AME) Posts Quarterly Earnings Results, Beats Estimates By $0.07 EPS

AMETEK (NYSE:AME) issued its quarterly earnings data on Tuesday. The technology company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.94 by $0.07, Briefing.com reports. AMETEK had a net margin of 20.50% and a return on equity of 16.66%. AMETEK’s revenue was up 13.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.87 earnings per share. AMETEK updated its Q1 2026 guidance to 1.850-1.900 EPS and its FY 2026 guidance to 7.870-8.070 EPS.

AMETEK Stock Up 2.0%

NYSE AME opened at $228.48 on Tuesday. The company has a current ratio of 1.16, a quick ratio of 0.72 and a debt-to-equity ratio of 0.14. The company has a market cap of $52.60 billion, a price-to-earnings ratio of 36.04, a PEG ratio of 3.05 and a beta of 1.03. The company has a 50 day moving average of $208.39 and a 200-day moving average of $194.48. AMETEK has a 1-year low of $145.02 and a 1-year high of $229.03.

AMETEK Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, December 19th. Stockholders of record on Friday, December 5th were issued a dividend of $0.31 per share. The ex-dividend date of this dividend was Friday, December 5th. This represents a $1.24 annualized dividend and a dividend yield of 0.5%. AMETEK’s dividend payout ratio (DPR) is currently 19.56%.

Insider Buying and Selling at AMETEK

In related news, insider Thomas C. Marecic sold 14,310 shares of the firm’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $202.11, for a total value of $2,892,194.10. Following the transaction, the insider owned 42,589 shares in the company, valued at approximately $8,607,662.79. This trade represents a 25.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Thomas M. Montgomery sold 6,388 shares of the stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $205.05, for a total transaction of $1,309,859.40. Following the sale, the vice president owned 22,116 shares in the company, valued at $4,534,885.80. The trade was a 22.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 137,088 shares of company stock valued at $27,212,340 in the last three months. Corporate insiders own 0.57% of the company’s stock.

Institutional Trading of AMETEK

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. CIBC Bancorp USA Inc. bought a new stake in shares of AMETEK in the 3rd quarter valued at about $5,990,000. Advisory Services Network LLC bought a new position in shares of AMETEK during the 3rd quarter worth about $92,000. Morningstar Investment Management LLC acquired a new position in AMETEK during the 3rd quarter worth approximately $925,000. NewEdge Advisors LLC grew its position in AMETEK by 12.8% in the 3rd quarter. NewEdge Advisors LLC now owns 4,451 shares of the technology company’s stock valued at $837,000 after purchasing an additional 505 shares during the period. Finally, CANADA LIFE ASSURANCE Co grew its holdings in shares of AMETEK by 3.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 351,093 shares of the technology company’s stock valued at $65,585,000 after buying an additional 11,235 shares during the last quarter. Institutional investors own 87.43% of the company’s stock.

Key Stories Impacting AMETEK

Here are the key news stories impacting AMETEK this week:

• Positive Sentiment: Reported record fourth‑quarter and full‑year 2025 results, reinforcing underlying business strength. AMETEK Announces Record Fourth Quarter and Full Year Results
• Positive Sentiment: Completed acquisition of LKC Technologies (adds ophthalmic diagnostic capabilities), expanding AMETEK’s medical/diagnostics exposure and product portfolio. AMETEK Acquires LKC Technologies DW Healthcare Partners Announces Sale of LKC Technologies to AMETEK
• Neutral Sentiment: Pre‑earnings coverage and previews highlight improving process markets and set context for investor expectations ahead of management commentary. Ametek Earnings on Deck as Process Markets Show Signs of Life Ametek Q4 2025 Earnings Preview
• Negative Sentiment: Updated FY‑2026 EPS guidance of $7.87–$8.07 is slightly below the consensus of $8.00, signaling more modest full‑year growth than investors expected.
• Negative Sentiment: Q1‑2026 EPS guidance of $1.85–$1.90 is at/just below the $1.90 consensus; revenue guidance centered around ~$1.9B also met modest expectations — collectively this conservative near‑term outlook is pressuring the stock.
• Negative Sentiment: Giverny Capital trimmed its AMETEK position, citing valuation, which is a small negative signal about investor positioning. Giverny Capital Asset Management Trimmed Ametek (AME) on Valuation

Analysts Set New Price Targets

Several equities research analysts have commented on AME shares. DA Davidson boosted their target price on AMETEK from $235.00 to $240.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Oppenheimer downgraded shares of AMETEK from an “outperform” rating to a “market perform” rating in a research note on Tuesday, January 27th. KeyCorp upped their target price on AMETEK from $220.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft started coverage on AMETEK in a research note on Wednesday, January 21st. They set a “buy” rating and a $271.00 price objective on the stock. Finally, Royal Bank Of Canada raised their target price on shares of AMETEK from $212.00 to $229.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, AMETEK presently has an average rating of “Moderate Buy” and a consensus target price of $229.82.

AMETEK Company Profile

AMETEK, Inc is a global manufacturer of electronic instruments and electromechanical devices that serves a broad range of industries. Headquartered in Berwyn, Pennsylvania, the company designs and produces precision instruments, electronic measurement devices, specialty sensors, and electric motors and motion control systems. Its product portfolio includes analytical and monitoring instruments, calibration equipment, power supplies, embedded electronics, and industrial motors and drives used for critical applications.

The company operates through two primary business platforms — an electronic instruments group focused on analytical, test and measurement and sensor products, and an electromechanical group that supplies motors, actuators, and related power and motion solutions.